Latest News-EVEREST MEDICINES Mediaroom_Page

Everest Medicines Announces Approval of Clinical Trial Application by China NMPA for Phase 3 Trial of Xerava(TM) for Community-Acquired Bacterial Pneumonia

SHANGHAI, Aug. 5, 2021 /PRNewswire/ -- Everest Medicines

2021-08-05 13:12 3716

Everest Medicines Receives Pediatric and Rare Severe Disease Priority Review Designation from Taiwan FDA for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer

SHANGHAI, July 29, 2021 /PRNewswire/ -- Everest Medicines

2021-07-29 18:41 3956

Everest Medicines Announces Strategic Collaboration with MediTrust Health Co., Ltd to Develop Novel Payment Solutions for Patients in China

SHANGHAI, July 20, 2021 /PRNewswire/ -- Everest Medicines

2021-07-20 18:42 4080

Everest Medicines Announces Strategic Collaboration with Medbanks Health Technology to Develop Innovative Healthcare Service Solutions for Patients in China

SHANGHAI, July 13, 2021 /PRNewswire/ -- Everest Medicines

2021-07-13 19:47 5555

Everest Medicines Announces Strategic Commercial Partnership with Global Technology Company, Tencent

SHANGHAI, July 12, 2021 /PRNewswire/ -- Everest Medicines

2021-07-12 12:42 3847

Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206 in ex-U.S. and ex-Asia Territories

SHANGHAI, July 5, 2021 /PRNewswire/ -- Everest Medicines

2021-07-05 18:16 2727

Everest Medicines Announces China NMPA Has Granted Priority Review for Sacituzumab Govitecan-hziy in Metastatic Triple-Negative Breast Cancer

SHANGHAI, May 20, 2021 /PRNewswire/ -- Everest Medicines

2021-05-20 19:04 4514

Everest Medicines Announces China NMPA Has Accepted Biologics License Application for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer

SHANGHAI, May 17, 2021 /PRNewswire/ -- Everest Medicines

2021-05-17 16:51 3023

Everest Medicines Receives Orphan Drug Designation from the Ministry of Food and Drug Safety in South Korea for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer

SHANGHAI, May 6, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical compa...

2021-05-06 08:30 3217

Everest Medicines Appoints Jennifer Yang as Chief Scientific Officer

SHANGHAI, April 15, 2021 /PRNewswire/ -- Everest Medicines

2021-04-15 08:36 4915

Everest Medicines Announces that the US FDA has Granted Licensing Partner Gilead Sciences, Inc. Accelerated Approval of Trodelvy® for the Treatment of Metastatic Urothelial Cancer

SHANGHAI, April 14, 2021 /PRNewswire/ -- Everest Medicines

2021-04-14 21:33 5962

Everest Medicines Announces that Licensing Partner Gilead Sciences, Inc. has Received Full US FDA Approval of Trodelvy® for the Treatment of Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

SHANGHAI, April 9, 2021 /PRNewswire/ -- Everest Medicines

2021-04-09 08:30 5575

Everest Medicines Announces China NMPA Approval of Clinical Trial Application to Evaluate Trodelvy® in a Phase 2 Basket Trial for a Variety of Cancers with High TROP-2 Expression

SHANGHAI, March 31, 2021 /PRNewswire/ -- Everest Medicines

2021-03-31 10:27 3267

Everest Medicines Announces Financial Results for Full Year Ended December 31, 2020

SHANGHAI, March 22, 2021 /PRNewswire/ -- Everest Medicines

2021-03-22 15:06 2585

Everest Medicines Announces Acceptance of New Drug Application by China NMPA for Xerava(TM) for the Treatment of Complicated Intra-abdominal Infections

SHANGHAI, March 22, 2021 /PRNewswire/ -- Everest Medicines

2021-03-22 10:40 3213

Everest Medicines to Announce Full-Year 2020 Financial Results on March 22, 2021

SHANGHAI, March 19, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical comp...

2021-03-19 14:43 4317

Everest Medicines Announces Selection as a Constituent of Certain Indexes of Hang Seng Indexes Company Limited

SHANGHAI, March 1, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical compa...

2021-03-01 12:36 3875

Everest Medicines Appoints Kevin Guo as Chief Commercial Officer

SHANGHAI, Feb. 18, 2021 /PRNewswire/ -- Everest Medicines

2021-02-18 12:26 5788

Everest Medicines Appoints Kevin Guo as Chief Commercial Officer

SHANGHAI, Feb. 18, 2021 /PRNewswire/ -- Everest Medicines

2021-02-18 12:21 2975

Everest Medicines Announces Amended Agreement with Spero Therapeutics

SHANGHAI, Jan. 18, 2021 /PRNewswire/ -- Everest Medicines, a biopharmaceutical company focused on d...

2021-01-18 18:05 5580